Tone mix
Week by week 52 weeks
Share of AstraZeneca PLC's 1,318 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Dec 29, 2025 · tone -25AstraZeneca sues over 'widespread defects' at Cambridge HQ-84
- Week of Sep 21, 2026 · tone +85AstraZeneca and Daiichi Sankyo's Breast Cancer Drug Approved for NHS Use in England+79
- Week of Jan 12, 2026 · tone -2Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits-50
- Week of Dec 22, 2025 · tone +11Jacobio, AstraZeneca ink cancer drug deal-48
- Week of Jul 6, 2026 · tone -25FTSE 100 Down 0.8%; AstraZeneca Tanks Nearly 10%-46
- Week of May 25, 2026 · tone -1AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC-40
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about AstraZeneca PLC in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 29 | +71 |
| Last 30 sessions | 137 | +63 |
| Last 90 sessions | 493 | +22 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 28, 2026
4 headlines, average tone +25: 1 positive, 3 neutral and 0 negative. Showing all 4.
- www.simcoereformer.ca · 9 outletsBreast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship ResearchNeutral
- www.proactiveinvestors.com · 1 outletAstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorganPositive
- www.tickerreport.com · 1 outletAstraZeneca Plc $AZN Shares Newly Purchased by Oakworth Capital Inc.Neutral
- www.tickerreport.com · 1 outletLifecore Biomedical (NASDAQ:LFCR) & AstraZeneca (NYSE:AZN) Head-To-Head ContrastNeutral
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research | www.simcoereformer.ca | 9 | Neutral |
| AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan | www.proactiveinvestors.com | 1 | Positive |
| AstraZeneca Plc $AZN Shares Newly Purchased by Oakworth Capital Inc. | www.tickerreport.com | 1 | Neutral |
| Lifecore Biomedical (NASDAQ:LFCR) & AstraZeneca (NYSE:AZN) Head-To-Head Contrast | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
6 headlines, average tone +82: 5 positive, 1 neutral and 0 negative. Showing all 6.
- www.tickerreport.com · 2 outletsAstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor UpdateNeutral
- www.rttnews.com · 1 outletAstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock UpPositive
- www.rttnews.com · 1 outletAstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock UpPositive
- www.rttnews.com · 1 outletAstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth BeyondPositive
- www.bioxconomy.com · 1 outletAstraZeneca to use Oracle AI to speed trial recruitmentPositive
- www.rttnews.com · 1 outletAmgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung CancerPositive
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update | www.tickerreport.com | 2 | Neutral |
| AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up | www.rttnews.com | 1 | Positive |
| AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up | www.rttnews.com | 1 | Positive |
| AstraZeneca Projects $80 Bln In Total Revenue By 2030, Sustained Growth Beyond | www.rttnews.com | 1 | Positive |
| AstraZeneca to use Oracle AI to speed trial recruitment | www.bioxconomy.com | 1 | Positive |
| Amgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
6 headlines, average tone +96: 6 positive, 0 neutral and 0 negative. Showing all 6.
- econotimes.com · 1 outletAstraZeneca Drug Doubles Survival in Later-Line CLDN18.2 Cancer TrialPositive
- www.thenationalnews.com · 1 outletAstraZeneca and Cleveland Clinic Abu Dhabi team up for $50 million clinical trials action planPositive
- www.moneycontrol.com · 1 outletAmgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58%Positive
- en.shafaqna.com · 1 outletastrazeneca stomach cancer drug | sone-ve survival boostPositive
- www.finanznachrichten.de · 1 outletAstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancerPositive
- zenopa.com · 1 outletAstraZeneca Taps Oracle for AI Clinical Trial Enrolment - Pharmaceutical Industry NewsPositive
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AstraZeneca Drug Doubles Survival in Later-Line CLDN18.2 Cancer Trial | econotimes.com | 1 | Positive |
| AstraZeneca and Cleveland Clinic Abu Dhabi team up for $50 million clinical trials action plan | www.thenationalnews.com | 1 | Positive |
| Amgen-AstraZeneca drug combination cut risk of death in small cell lung cancer by 58% | www.moneycontrol.com | 1 | Positive |
| astrazeneca stomach cancer drug | sone-ve survival boost | en.shafaqna.com | 1 | Positive |
| AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer | www.finanznachrichten.de | 1 | Positive |
| AstraZeneca Taps Oracle for AI Clinical Trial Enrolment - Pharmaceutical Industry News | zenopa.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.sierraleonetimes.com · 22 outletsP&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain AwardsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards | www.sierraleonetimes.com | 22 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
4 headlines, average tone +50: 2 positive, 2 neutral and 0 negative. Showing all 4.
- english.aawsat.com · 1 outletAstraZeneca Says FDA Approves Drug for Rare Kidney Disease in AdultsPositive
- www.rttnews.com · 1 outletAstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgANPositive
- www.insidermonkey.com · 1 outletIs AstraZeneca (AZN) Stock Cheap? - Insider MonkeyNeutral
- www.insidermonkey.com · 1 outletAbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story?Neutral
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AstraZeneca Says FDA Approves Drug for Rare Kidney Disease in Adults | english.aawsat.com | 1 | Positive |
| AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN | www.rttnews.com | 1 | Positive |
| Is AstraZeneca (AZN) Stock Cheap? - Insider Monkey | www.insidermonkey.com | 1 | Neutral |
| AbbVie vs. AstraZeneca: Which Pharma Giant Has the Stronger Earnings Growth Story? | www.insidermonkey.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about AstraZeneca PLC, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.